The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

May 25, 2023

Study Completion Date

May 25, 2023

Conditions
Cardiovascular DiseasesCardiovascular Risk FactorTriglycerides HighDiabetes Mellitus, Type 2
Interventions
DRUG

Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]

2 x 1g capsules BID as per REDUCE-IT

Trial Locations (3)

L1H 1B9

The Oshawa Clinic, Oshawa

M1S4N6

Diagnostic Assessment Centre, Scarborough Village

L4L 0K8

Langstaff Medical Clinic, Vaughan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

HLS Therapeutics, Inc

UNKNOWN

collaborator

Unity Health Toronto

OTHER

collaborator

Western University, Canada

OTHER

lead

Canadian Medical and Surgical Knowledge Translation Research Group

OTHER

NCT04562467 - The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk | Biotech Hunter | Biotech Hunter